Proliferative Diabetic Retinopathy (PDR)NCT07586787
Early Vitrectomy vs PRP in Early Proliferative Diabetic Retinopathy
A study testing Microincision Vitrectomy Surgery and Panretinal Photocoagulation in people with Proliferative Diabetic Retinopathy (PDR), run by Xiamen Ophthalmology Center Affiliated to Xiamen University at 6 sites in China.
Trial summary
The goal of this clinical trial is to learn whether early microincision vitrectomy surgery (MIVS) can improve retinal neovascularization outcomes compared to standard pan-retinal photocoagulation (PRP) in patients with early proliferative diabetic retinopathy (PDR). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Proliferative Diabetic Retinopathy (PDR)
- What is being tested?
- Microincision Vitrectomy Surgery and Panretinal Photocoagulation
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 100 participants
- Where
- 6 sitesChina
- Study dates
- 1 Jan 2025to 10 Jun 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age 18 years or older.
- Diagnosis of type 2 diabetes mellitus.
- Presence of early proliferative diabetic retinopathy with active neovascularization, or mild vitreous hemorrhage or preretinal hemorrhage that does not interfere with evaluation of neovascularization.
- Relatively clear optical media, good pupillary dilation, and sufficient cooperation for panretinal photocoagulation and retinal imaging.
- Ability and willingness to provide written informed consent.
- If both eyes are eligible, the eye with worse vision will be included.
Who cannot join
- Prior panretinal photocoagulation, macular photocoagulation, or vitrectomy in the study eye.
- Retinal traction or retinal detachment.
- Optic neuropathy.
- Macular edema caused by reasons other than diabetes.
- Coexisting ocular disease that may decrease visual acuity during the study.
- Substantial cataract likely to decrease visual acuity by more than three lines.
Show all 19Show fewer
- Major ocular surgery within the past 4 months or planned intraocular surgery within the next 6 months.
- YAG capsulotomy within the past 2 months.
- Any intravitreal injection within the past 3 months.
- Aphakia.
- Severe external ocular infection.
- Uncontrolled glaucoma.
- Significant renal disease requiring dialysis or kidney transplantation.
- Unstable glycemic control.
- Blood pressure greater than 180/110 mmHg.
- History of transient ischemic attack, stroke, myocardial infarction, acute congestive heart failure, or other acute cardiac event requiring hospitalization within the past 4 months.
- Pregnant, lactating, or intending to become pregnant during the study period.
- Participation in another clinical trial.
- Unwilling or unable to provide informed consent, undergo randomization, or return for scheduled visits.
Trial locations and contacts
6 sites in 1 country. Contact the study team or a site near you to ask about taking part.
6 sites in 1 country
China6 sites, 1 recruiting
- Completed
Peking University People's Hospital
Beijing, Beijing Municipality
- Completed
The First Affiliated Hospital of Dalian Medical University
Dalian, Liaoning
- Completed
Jiangsu Provincial People's Hospital
Nanjing, Jiangsu
- Completed
Nanjing Medical University affiliated Eye Hospital
Nanjing, Jiangsu
- Recruiting
Xiamen Eye Center of Xiamen University
Xiamen, Fujian, 361000
Xiuju Chen, MD, 15121013344, joyychen@aliyun.com
Xiaoxin Li, PhD
- Completed
Henan Province People's Hospital
Zhengzhou, Henan
About this study
Official title: Comparison of Early Micro-invasive Vitrectomy Surgery Versus Panretinal Photocoagulation for the Treatment of Early Proliferative Diabetic Retinopathy: A Multi-center Randomized Trial
The goal of this clinical trial is to learn whether early microincision vitrectomy surgery (MIVS) can improve retinal neovascularization outcomes compared to standard pan-retinal photocoagulation (PRP) in patients with early proliferative diabetic retinopathy (PDR). It will also evaluate the safety and functional outcomes of early surgical intervention in this population.
The main questions it aims to answer are:
Read more
Does early MIVS increase the proportion of eyes achieving complete regression of retinal neovascularization at 12 months? Does early MIVS improve visual and functional outcomes, including visual acuity and visual field, compared to PRP? Researchers will compare early MIVS combined with peripheral scatter photocoagulation to standard PRP to determine whether early surgical intervention leads to better regression of neovascularization and improved clinical outcomes.
Participants will:
Receive either MIVS with peripheral photocoagulation or standard PRP Undergo retinal imaging assessments including fundus fluorescein angiography (FFA) or optical coherence tomography angiography (OCTA) Complete follow-up visits over 12 months, including visual acuity testing, visual field testing, and optical coherence tomography (OCT) imaging Be monitored for the occurrence of vitreous hemorrhage and other clinical outcomes
Read the detailed description
Diabetic retinopathy is a leading cause of vision impairment worldwide, particularly among working-age adults. The development of retinal neovascularization in proliferative diabetic retinopathy (PDR), including neovascularization at the disc (NVD) and neovascularization elsewhere (NVE), is associated with a high risk of vitreous hemorrhage, tractional retinal detachment, and severe vision loss.
Current standard treatment for early PDR includes panretinal photocoagulation (PRP) with or without adjunctive anti-vascular endothelial growth factor (anti-VEGF) therapy. While PRP has been shown to reduce the risk of severe vision loss, it is associated with several limitations, including peripheral visual field loss, reduced night vision, exacerbation of macular edema, and incomplete regression of neovascularization in a substantial proportion of patients. Anti-VEGF therapy requires repeated intravitreal injections and may be associated with treatment burden and variable response.
The vitreous body plays an important role in the pathophysiology of PDR by providing a scaffold for neovascular growth and contributing to the persistence of vascular endothelial growth factor (VEGF) within the vitreous cavity. Microincision vitrectomy surgery (MIVS) may offer potential therapeutic advantages by removing the vitreous scaffold, facilitating the clearance of VEGF, and improving intraocular oxygenation. These mechanisms may contribute to more effective regression of retinal neovascularization and reduction in disease progression.
This study is a multicenter, prospective trial designed to compare early MIVS intervention with standard PRP in patients with early PDR. Eligible participants will receive either MIVS combined with peripheral photocoagulation or standard PRP. The surgical procedure will be performed using small-gauge (25G or 27G) instrumentation with high-speed vitreous removal. In the experimental group, scattered photocoagulation will be applied to the far peripheral retina during surgery. In the control group, PRP will be delivered in accordance with standard clinical practice over multiple sessions.
Participants will undergo standardized follow-up evaluations over 12 months. Retinal neovascularization will be assessed using fundus fluorescein angiography (FFA) or optical coherence tomography angiography (OCTA). Functional outcomes, including best corrected visual acuity (BCVA) and visual field cumulated values , will be measured using standardized protocols. Structural outcomes such as central retinal thickness will be assessed by optical coherence tomography (OCT).
To enhance the reliability of outcome assessment, retinal imaging will be obtained using standardized acquisition protocols and evaluated by trained graders when feasible.
This study aims to generate clinical evidence on whether early surgical intervention with MIVS can improve neovascular regression and functional outcomes compared with PRP alone in early PDR, thereby informing optimal treatment strategies for this patient population.
- Conditions
- Proliferative Diabetic Retinopathy (PDR)
- Being tested
- Microincision Vitrectomy Surgery, Panretinal Photocoagulation
- Keywords
- Panretinal photocoagulation, Proliferative diabetic retinopathy, Retinal neovascularization, Vitrectomy
- Medical subject headings
- Retinal Neovascularization
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Microincision Vitrectomy SurgeryProcedure or surgery
Also called Panretinal Photocoagulation
Panretinal photocoagulation delivered using standard laser therapy, consisting of approximately 1000 to 1500 laser burns applied over one or two sessions according to routine clinical practice.
Panretinal PhotocoagulationProcedure or surgery
Panretinal photocoagulation delivered using standard laser therapy, consisting of approximately 1000 to 1500 laser burns applied over one or two sessions according to routine clinical practice.
| Study group | Role | What they receive |
|---|---|---|
| Microincision Vitrectomy Surgery | Experimental | Participants undergo early microincision vitrectomy surgery (MIVS) using small-gauge instrumentation (25G or 27G) with high-speed vitreous removal. During surgery, scattered photocoagulation is applied to the far peripheral retina. Receives: Procedure: Microincision Vitrectomy Surgery |
| Panretinal Photocoagulation | Active comparator | Participants receive standard panretinal photocoagulation (PRP) according to routine clinical practice. Treatment consists of approximately 1000 to 1500 laser burns delivered over one or two sessions within several weeks after randomization. Receives: Procedure: Panretinal Photocoagulation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Proportion of Eyes With Complete Regression of Neovascularization
Complete regression is defined as absence of neovascularization at the disc or neovascularization elsewhere in the retina, assessed by fundus fluorescein angiography or optical coherence tomography angiography.
Measured: 12 months
Secondary outcomes (4)
Proportion of Eyes With Partial Regression of Neovascularization
Partial regression is defined as reduction in retinal neovascularization compared with baseline, assessed by fundus fluorescein angiography or optical coherence tomography angiography.
Measured: 12 months
Incidence of Vitreous Hemorrhage
Incidence of vitreous hemorrhage through 6/12 months after treatment.
Measured: 6 months；12 months
Change in Visual Field
Change in visual field cumulative values measured using the 60-degree visual field test.
Measured: Baseline to 12 months
Change in Best Corrected Visual Acuity
Change in best corrected visual acuity measured using an ETDRS LogMAR chart.
Measured: Baseline to 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 May 2026
- Study start1 Jan 2025
- Primary completion10 Jun 2026 (estimated)
- Study completion10 Jun 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (7)Papers the sponsor has linked to this study.
- Other trials for Proliferative Diabetic Retinopathy (PDR)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Xiamen Ophthalmology Center Affiliated to Xiamen University
- Sponsor type
- University, hospital or other
- Collaborators
- Jiangsu Provincial People's Hospital, Peking University People's Hospital, Henan Provincial People's Hospital, Nanjing Medical University, The First Affiliated Hospital of Dalian Medical University
- Responsible party
- Sponsor
- Investigators
- Xiaoxin Li, PhD, Principal investigator, Xiamen Eye Center of Xiamen University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07586787
- Sponsor's protocol ID
- XMYKZX-KY-2024-061
- Other IDs
- IIT-92241613
- Status last verified
- May 2026
- First submitted
- 7 May 2026
- Last updated
- 14 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be publicly available but may be shared upon reasonable request and with approval from the study sponsor and institutional review board.
Publications
Simpson AR, Dowell NG, Jackson TL, Tofts PS, Hughes EH. Measuring the effect of pars plana vitrectomy on vitreous oxygenation using magnetic resonance imaging. Invest Ophthalmol Vis Sci. 2013 Mar 21;54(3):2028-34. doi: 10.1167/iovs.12-11258.
PubMed 23439600Jones CH, Gui W, Schumann RG, Boneva S, Lange CA, van Overdam K, Chui TY, Rosen RB, Engelbert M, Sebag J. Hyalocytes in proliferative vitreo-retinal diseases. Expert Rev Ophthalmol. 2022;17(4):263-280. doi: 10.1080/17469899.2022.2100764. Epub 2022 Sep 6.
PubMed 36466118Vaz-Pereira S, Dansingani KK, Chen KC, Cooney MJ, Klancnik JM Jr, Engelbert M. TOMOGRAPHIC RELATIONSHIPS BETWEEN RETINAL NEOVASCULARIZATION AND THE POSTERIOR VITREOUS IN PROLIFERATIVE DIABETIC RETINOPATHY. Retina. 2017 Jul;37(7):1287-1296. doi: 10.1097/IAE.0000000000001336.
PubMed 27749694Gawecki M, Kicinski K, Bianco L, Battaglia Parodi M. Regression of Neovascularization after Panretinal Photocoagulation Combined with Anti-VEGF Injection for Proliferative Diabetic Retinopathy-A Review. Diagnostics (Basel). 2023 Dec 22;14(1):31. doi: 10.3390/diagnostics14010031.
PubMed 38201340Bahr TA, Bakri SJ. Update on the Management of Diabetic Retinopathy: Anti-VEGF Agents for the Prevention of Complications and Progression of Nonproliferative and Proliferative Retinopathy. Life (Basel). 2023 Apr 27;13(5):1098. doi: 10.3390/life13051098.
PubMed 37240743Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991 May;98(5 Suppl):823-33.
PubMed 2062515Berrocal MH, Acaba-Berrocal L. Early pars plana vitrectomy for proliferative diabetic retinopathy: update and review of current literature. Curr Opin Ophthalmol. 2021 May 1;32(3):203-208. doi: 10.1097/ICU.0000000000000760.
PubMed 33770016
Study at a glance
From the registry record, last updated by the sponsor on 14 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of Early Micro-invasive Vitrectomy Surgery Versus Panretinal Photocoagulation for the Treatment of Early Proliferative Diabetic Retinopathy: A Multi-center Randomized Trial
- ClinicalTrials.gov ID
- NCT07586787
- Acronym / sponsor ID
- XMYKZX-KY-2024-061
- Conditions
- Proliferative Diabetic Retinopathy (PDR)
- Keywords
- Panretinal photocoagulation, Proliferative diabetic retinopathy, Retinal neovascularization, Vitrectomy
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Xiamen Ophthalmology Center Affiliated to Xiamen UniversityUniversity, hospital or other
- Collaborators
- Jiangsu Provincial People's Hospital, Peking University People's Hospital, Henan Provincial People's Hospital, Nanjing Medical University, The First Affiliated Hospital of Dalian Medical University
- Study start
- 1 Jan 2025 (actual)
- Primary completion
- 10 Jun 2026 (estimated)
- Study completion
- 10 Jun 2026 (estimated)
- First posted
- 14 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn whether early microincision vitrectomy surgery (MIVS) can improve retinal neovascularization outcomes compared to standard pan-retinal photocoagulation (PRP) in patients with early proliferative diabetic retinopathy (PDR). It will also evaluate the safety and functional outcomes of early surgical intervention in this population.
The main questions it aims to answer are:
Does early MIVS increase the proportion of eyes achieving complete regression of retinal neovascularization at 12 months? Does early MIVS improve visual and functional outcomes, including visual acuity and visual field, compared to PRP? Researchers will compare early MIVS combined with peripheral scatter photocoagulation to standard PRP to determine whether early surgical intervention leads to better regression of neovascularization and improved clinical outcomes.
Participants will:
Receive either MIVS with peripheral photocoagulation or standard PRP Undergo retinal imaging assessments including fundus fluorescein angiography (FFA) or optical coherence tomography angiography (OCTA) Complete follow-up visits over 12 months, including visual acuity testing, visual field testing, and optical coherence tomography (OCT) imaging Be monitored for the occurrence of vitreous hemorrhage and other clinical outcomes
Detailed description
Diabetic retinopathy is a leading cause of vision impairment worldwide, particularly among working-age adults. The development of retinal neovascularization in proliferative diabetic retinopathy (PDR), including neovascularization at the disc (NVD) and neovascularization elsewhere (NVE), is associated with a high risk of vitreous hemorrhage, tractional retinal detachment, and severe vision loss.
Current standard treatment for early PDR includes panretinal photocoagulation (PRP) with or without adjunctive anti-vascular endothelial growth factor (anti-VEGF) therapy. While PRP has been shown to reduce the risk of severe vision loss, it is associated with several limitations, including peripheral visual field loss, reduced night vision, exacerbation of macular edema, and incomplete regression of neovascularization in a substantial proportion of patients. Anti-VEGF therapy requires repeated intravitreal injections and may be associated with treatment burden and variable response.
The vitreous body plays an important role in the pathophysiology of PDR by providing a scaffold for neovascular growth and contributing to the persistence of vascular endothelial growth factor (VEGF) within the vitreous cavity. Microincision vitrectomy surgery (MIVS) may offer potential therapeutic advantages by removing the vitreous scaffold, facilitating the clearance of VEGF, and improving intraocular oxygenation. These mechanisms may contribute to more effective regression of retinal neovascularization and reduction in disease progression.
This study is a multicenter, prospective trial designed to compare early MIVS intervention with standard PRP in patients with early PDR. Eligible participants will receive either MIVS combined with peripheral photocoagulation or standard PRP. The surgical procedure will be performed using small-gauge (25G or 27G) instrumentation with high-speed vitreous removal. In the experimental group, scattered photocoagulation will be applied to the far peripheral retina during surgery. In the control group, PRP will be delivered in accordance with standard clinical practice over multiple sessions.
Participants will undergo standardized follow-up evaluations over 12 months. Retinal neovascularization will be assessed using fundus fluorescein angiography (FFA) or optical coherence tomography angiography (OCTA). Functional outcomes, including best corrected visual acuity (BCVA) and visual field cumulated values , will be measured using standardized protocols. Structural outcomes such as central retinal thickness will be assessed by optical coherence tomography (OCT).
To enhance the reliability of outcome assessment, retinal imaging will be obtained using standardized acquisition protocols and evaluated by trained graders when feasible.
This study aims to generate clinical evidence on whether early surgical intervention with MIVS can improve neovascular regression and functional outcomes compared with PRP alone in early PDR, thereby informing optimal treatment strategies for this patient population.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Microincision Vitrectomy Surgery | Experimental | Procedure: Microincision Vitrectomy SurgeryParticipants undergo early microincision vitrectomy surgery (MIVS) using small-gauge instrumentation (25G or 27G) with high-speed vitreous removal. During surgery, scattered photocoagulation is applied to the far peripheral retina. |
| Panretinal Photocoagulation | Active comparator | Procedure: Panretinal PhotocoagulationParticipants receive standard panretinal photocoagulation (PRP) according to routine clinical practice. Treatment consists of approximately 1000 to 1500 laser burns delivered over one or two sessions within several weeks after randomization. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Age 18 years or older.
- Diagnosis of type 2 diabetes mellitus.
- Presence of early proliferative diabetic retinopathy with active neovascularization, or mild vitreous hemorrhage or preretinal hemorrhage that does not interfere with evaluation of neovascularization.
- Relatively clear optical media, good pupillary dilation, and sufficient cooperation for panretinal photocoagulation and retinal imaging.
- Ability and willingness to provide written informed consent.
Key exclusion criteria (19 listed)
- Prior panretinal photocoagulation, macular photocoagulation, or vitrectomy in the study eye.
- Retinal traction or retinal detachment.
- Optic neuropathy.
- Macular edema caused by reasons other than diabetes.
- Coexisting ocular disease that may decrease visual acuity during the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Microincision Vitrectomy SurgeryAlso: Panretinal PhotocoagulationPanretinal photocoagulation delivered using standard laser therapy, consisting of approximately 1000 to 1500 laser burns applied over one or two sessions according to routine clinical practice. | Procedure or surgery | Microincision Vitrectomy Surgery |
| Panretinal PhotocoagulationPanretinal photocoagulation delivered using standard laser therapy, consisting of approximately 1000 to 1500 laser burns applied over one or two sessions according to routine clinical practice. | Procedure or surgery | Panretinal Photocoagulation |
Primary outcome
Proportion of Eyes With Complete Regression of Neovascularization
Time frame: 12 months
Complete regression is defined as absence of neovascularization at the disc or neovascularization elsewhere in the retina, assessed by fundus fluorescein angiography or optical coherence tomography angiography.
4 secondary outcomes
Proportion of Eyes With Partial Regression of Neovascularization
Time frame: 12 months
Incidence of Vitreous Hemorrhage
Time frame: 6 months；12 months
Change in Visual Field
Time frame: Baseline to 12 months
Change in Best Corrected Visual Acuity
Time frame: Baseline to 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 May 2026.
- Background: PubMed 23439600Simpson AR, Dowell NG, Jackson TL, Tofts PS, Hughes EH. Measuring the effect of pars plana vitrectomy on vitreous oxygenation using magnetic resonance imaging. Invest Ophthalmol Vis Sci. 2013 Mar 21;54(3):2028-34. doi: 10.1167/iovs.12-11258.
- Background: PubMed 36466118Jones CH, Gui W, Schumann RG, Boneva S, Lange CA, van Overdam K, Chui TY, Rosen RB, Engelbert M, Sebag J. Hyalocytes in proliferative vitreo-retinal diseases. Expert Rev Ophthalmol. 2022;17(4):263-280. doi: 10.1080/17469899.2022.2100764. Epub 2022 Sep 6.
- Background: PubMed 27749694Vaz-Pereira S, Dansingani KK, Chen KC, Cooney MJ, Klancnik JM Jr, Engelbert M. TOMOGRAPHIC RELATIONSHIPS BETWEEN RETINAL NEOVASCULARIZATION AND THE POSTERIOR VITREOUS IN PROLIFERATIVE DIABETIC RETINOPATHY. Retina. 2017 Jul;37(7):1287-1296. doi: 10.1097/IAE.0000000000001336.
- Background: PubMed 38201340Gawecki M, Kicinski K, Bianco L, Battaglia Parodi M. Regression of Neovascularization after Panretinal Photocoagulation Combined with Anti-VEGF Injection for Proliferative Diabetic Retinopathy-A Review. Diagnostics (Basel). 2023 Dec 22;14(1):31. doi: 10.3390/diagnostics14010031.
- Background: PubMed 37240743Bahr TA, Bakri SJ. Update on the Management of Diabetic Retinopathy: Anti-VEGF Agents for the Prevention of Complications and Progression of Nonproliferative and Proliferative Retinopathy. Life (Basel). 2023 Apr 27;13(5):1098. doi: 10.3390/life13051098.
- Background: PubMed 2062515Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991 May;98(5 Suppl):823-33.
- Background: PubMed 33770016Berrocal MH, Acaba-Berrocal L. Early pars plana vitrectomy for proliferative diabetic retinopathy: update and review of current literature. Curr Opin Ophthalmol. 2021 May 1;32(3):203-208. doi: 10.1097/ICU.0000000000000760.
- Individual participant dataSharing planned: No. Individual participant data will not be publicly available but may be shared upon reasonable request and with approval from the study sponsor and institutional review board.
Related trials for Proliferative Diabetic Retinopathy (PDR)
RecruitingPhase 3
Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR
Proliferative Diabetic Retinopathy (PDR)
Active, not recruitingPhase 4
High Dose Eylea for Proliferative Diabetic Retinopathy Outcomes
Proliferative Diabetic Retinopathy (PDR)
RecruitingEarly Phase 1
The Preliminary Safety and Efficacy of RRG001 After Vitrectomy in Subjects With Proliferative Diabetic Retinopathy (PDR)
PDR - Proliferative Diabetic Retinopathy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Xiaoxin Li, PhD principal investigator
Xiamen Eye Center of Xiamen University
6 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Microincision Vitrectomy Surgery and Panretinal Photocoagulation in people with Proliferative Diabetic Retinopathy (PDR), run by Xiamen Ophthalmology Center Affiliated to Xiamen University at 6 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 14 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 6 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact xiuju Chen, md (+8618060955810, joyychen@aliyun.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Proportion of Eyes With Complete Regression of Neovascularization (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07586787, which also lists 7 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 May 2026; AzTrials last refreshed its copy on 6 Nov 2026.